Human Papillomavirus and Cervical Cancer by Okunade, Kehinde Sharafadeen
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Human Papillomavirus and 
Cervical Cancer
Kehinde Sharafadeen Okunade
Abstract
Cervical cancer is by far the most common HPV-related disease. About 99.7% 
of cervical cancer are caused by persistent genital high-risk human papillomavirus 
(HPV) infection. Worldwide, cervical cancer is one of the most common cancer in 
women with an estimated 528,000 new cases reported in 2012. Most HPV infec-
tions clear spontaneously but persistent infection with the oncogenic or high-risk 
types may cause cancer of the oropharynx and anogenital regions. The virus usually 
infects the mucocutaneous epithelium and produces viral particles in matured 
epithelial cells and then causes a disruption in normal cell-cycle control and the 
promotion of uncontrolled cell division leading to the accumulation of genetic dam-
age. There are currently two effective prophylactic vaccines against HPV infection 
in many developed countries and these comprise of HPV types 16 and 18, and HPV 
types 6, 11, 16 and 18 virus-like particles. HPV testing in the secondary prevention 
of cervical cancer is clinically valuable in triaging low-grade cytological abnormali-
ties and is also more sensitive than cytology as a primary screening. If these preven-
tion strategies can be implemented in both in developed and developing countries, 
many thousands of lives could be saved.
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1. Introduction
Human papillomavirus (HPV) is the commonest viral infection of the reproduc-
tive tract and is one of the most common causes of sexually transmitted infection 
worldwide [1]. Even though it is sexually transmitted, HPV transmission does 
not require penetrative sexual intercourse. Skin-to-skin genital contact is a well-
established mode of transmission. Over 70% of sexually active women and men 
will be infected at some point in their lives and some may even be infected on more 
than one occasion [2]. The peak period for acquiring HPV infection is shortly after 
becoming sexually active. The infection usually clears up spontaneously within a 
few months after the acquisition with about 90% clearing within 2 years. There are 
over 200 HPV types recognized based on DNA sequence data showing genomic 
differences, and many of these are harmless. HPV can infect basal epithelial cells 
of the mucocutaneous membrane, and it is associated with a variety of clinical 
conditions that range from innocuous lesions to cancer. Most of the infections are 
benign, causing lesions such as cutaneous warts on the hands, feet and anogenital 
regions. Warts are areas of hypertrophied skin filled with keratin and are mainly a 
cosmetic nuisance; generally, they resolve spontaneously within 1–5 years. Only a 
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small proportion of infections with certain types of HPV can persist and progress to 
cancer such as oropharyngeal, cervical, vulvar, vaginal and penile cancer [1].
Cervical cancer is by far the most common HPV-related disease [1]. Nearly all 
cases of cervical cancer are due to persistent or chronic HPV infection. Cervical 
cancer is the fourth most common cancer in women worldwide and it accounts 
for an estimated 528,000 new cases [2]. About 85% of the global burden occurs 
in the less developed regions, where it accounts for almost 12% of all female 
malignancies. In 2012, an estimated 266,000 deaths were attributed to cervical 
cancer, accounting for 7.5% of all female cancer deaths with almost 90% these 
deaths occurring in the less developed regions [2]. In these developing countries, 
cervical cancer may constitute up to 25% of all female cancer cases [3] and is only 
preceded by breast cancer as the most common cause of cancer deaths in women 
worldwide [4].
2. Basic virology of HPV
HPV is a member of the Papovaviridae family. It is a relatively small, non-
enveloped virus of about 55 nm diameter. It has an icosahedral capsid with 
72 capsomers and these contain at least two capsid proteins, L1 and L2. Each 
capsomer is a pentamer of the major capsid protein, L1 [5]. Each virion capsid 
contains about 12 copies of the minor capsid protein, L2 [6]. The HPV genome 
consists of a single molecule of double-stranded, circular DNA [7] with all Open 
Reading Frame (ORF) protein-coding sequences confined to one strand. There are 
three functional regions in the genome (Figure 1) [8]: The first is a “non-coding 
upstream regulatory region” also referred to as the long control region (LCR), 
or the upper regulatory region (URR). This region contains the highest degree 
of variation in the viral genome and contains the p97 core promoter along with 
enhancer and silencer sequences that control ORFs transcription in the regulation 
of DNA replication [9]. The second is called the “early region (E)” and it consists 
of ORFs E1, E2, E4, E5, E6, and E7, which are involved in viral replication and 
tumorigenesis. The third is referred to as the “late region (L)” and this encodes the 
L1 and L2 ORFs for the viral capsid. The E6, E7, and L1 ORFs of a new or unknown 
HPV type should be 90% or less homologous to the corresponding sequences of 
known HPV types [10].
Figure 1. 
Genome organization of HPV [9].
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3. Epidemiology of genital HPV infection
The worldwide prevalence of high-risk HPV infection is 10.4% [11] and it can 
be as high as 36.5% in some developing countries [12, 13]. Several epidemiologic 
studies have clearly shown that the risk of contracting genital high-risk HPV 
infection and cervical cancer is influenced by sexual activity [14, 15]. An individual 
is at increased risk of having HPV infection if he or she has had multiple sexual 
partners at any time or if he or she has a partner who has had multiple sexual 
partners. Having sexual activity at an early age as well as having a history of other 
sexually transmitted infections, genital warts, or cervical or penile cancer in an 
individual or sexual partner may also increase the risk of becoming infected with 
HPV. In addition to sexual activity, age is an important determinant of the risk of 
HPV infection [16, 17]. The infection is most common among sexually active young 
women between the age of 18 and 30 years with a sharp decline in prevalence after 
the age of 30 years. Although, cervical cancer is more common in older women of 
35 years and above, thus suggesting that the infection occurs at a younger age with 
a slow progression to cancer at an older age. Persistence of HPV infection is com-
moner with the high-risk or oncogenic types and this plays an important role in 
the development of invasive cancer of the cervix [1]. Cervical cancer arises at the 
transformation zone, which is the region between the squamous epithelium of the 
ectocervix and the columnar epithelium of the endocervix, where continuous meta-
plastic changes occur. The period of greatest metaplastic activity coincides with the 
greatest risk of HPV infection and this occurs at puberty and the first pregnancy 
and subsequently declines slowly after the occurrence of menopause.
4. Link between genital HPV infections and cervical cancer
In the past 3–4 decades, the natural history of cervical cancer has been well 
studied, and persistent infection of the cervix with certain types of HPV has been 
reported as a necessary causative factor for its occurrence [18]. The link between 
HPV and cervical squamous cell carcinoma has become well established since the 
early 1980. The magnitude of the association between HPV and squamous cell 
carcinoma of the cervix is higher than that for the association between smoking and 
lung cancer [19]. About 30 HPV types that are transmitted through sexual contact 
and infect primarily the cervix, vagina, vulva, penis, and anus have been identified. 
At least one of these HPV types has been implicated in 99.7% of cases of squamous 
cell carcinoma of the cervix [18]. HPV is a family of closely related viruses with each 
designated as a type based on their nucleic acid sequencing and then numbered in 
the order of discovery. More than 200 HPV types are known to exist [1, 20] with 15 
types associated with cervical cancer. Genital HPV types can be grouped as high-
risk (oncogenic) and low-risk (non-oncogenic) HPV types based on this association 
with cervical cancer and its precursor lesions. Low-risk or non-oncogenic HPV 
types include types 6, 11, 42, 43, and 44 while the high-risk or oncogenic HPV types 
include types 16, 18, 31, 33, 34, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 [18]. Low-
risk subtypes are also occasionally found in cervical carcinomas. The virus usually 
infects the mucocutaneous epithelium and produces viral particles in matured 
epithelial cells and then causes a disruption in normal cell-cycle control and the 
promotion of uncontrolled cell division leading to the accumulation of genetic 
damage [20]. Adenocarcinomas of the cervix are also less commonly related to HPV 
infection and is age dependent [21]. Almost 90% of adenocarcinoma of the cervix 
in women younger than 40 years of age are related to HPV infection, whereas it was 
observed in only 43% of adenocarcinomas in those aged 60 years and older. Most 
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HPV-induced cervical changes are transient with 90% regressing spontaneously 
within 12–36 months [22–26]. However, various other factors such as the individu-
al’s genetic predisposition, genetic variation within different HPV type, coinfection 
with more than one type of HPV, frequency of reinfection, hormone levels, and 
immune response may alter an individual’s ability to clear the infection. Therefore, 
detection of high-risk HPV is necessary but may not be enough for the develop-
ment of cervical cancer. Whether a woman will develop cervical cancer depends on 
several factors that act in conjunction with oncogenic HPV types in a process that 
leads to cervical cancer. These factors or modifiers of HPV activities include:
4.1 Suppressed primary immune response
Immune response to HPV infection is cell mediated and thus conditions that 
impair cell-mediated responses such as renal transplantation or HIV disease 
increase the risk of acquisition and progression of HPV [10, 27, 28]. Studies have 
consistently shown higher prevalence of HPV infection and cervical cancer precur-
sors in HIV infected women [29–31].
4.2 Long-term use of oral contraceptives
This is a significant risk factor for high-grade cervical disease according to some 
studies [16, 32]. This is because the upstream regulatory region of high-risk HPV 
contains sequences which are similar to the responsive elements of glucocorticoid 
that can be induced by steroid hormones such as progesterone which is the active 
component of oral contraceptives and dexamethasone.
4.3 Cigarette smoking
The suppression of local immune response induced by smoking and the muta-
genic activity of tobacco components have been demonstrated in cervical cells 
and this may contribute to HPV persistence or to malignant changes in the cervix 
[33–35]. It appears that smoking is the most important risk factor independent 
of HPV infection for high grade cervical disease [16]. Smoking shows little or no 
relationship to low grade cervical disease [1].
4.4 Increasing parity
Having an increasing number of full-term pregnancies is a significant indepen-
dent risk factor for persistent HPV infection and cervical cancer [36, 37]. The pos-
sible mechanisms proposed for this are the increased hormone levels and impaired 
immune response of pregnancies [38]. In multiparous women, the transformation 
zone remains longer on the ectocervix and this facilitates its direct exposure to the 
virus and other potential cofactors [39]. However, the most plausible mechanism 
is the local tissue damage occurring during vaginal childbirth or cellular oxidative 
stress with the increased likelihood of DNA damage and HPV integration [40, 41].
5. Prevention of HPV-associated cervical cancer
The natural history of cervical cancer offers unique opportunities for preven-
tion of the disease [42]. Conventionally, Pap smear and liquid-based cytology, 
combined with treatment of cervical pre-cancerous lesions and early-stage cancer, 
has been successful in preventing up to 80% of invasive cervical cancer cases in 
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the developed world [43, 44]. Cervical cancer screening involves testing for HPV 
infection and cervical cancer precursor lesions among women who have no symp-
toms. When screening detects cervical pre-cancerous lesions, treatment can easily 
be instituted, and cancer avoided. Screening can also detect early stage cervical 
cancer at a time when treatment has a high potential for cure. Currently, primary 
approaches to HPV prevention include both risk reduction and development of 
vaccines again HPV. The risk of contracting HPV may be decreased with the use of 
latex condoms and spermicides. However, these are not totally reliable, since HPV 
infection may be transmitted through contact with other parts of the body, such as 
the external genitalia, or anus, that are not protected by a condom [1].
5.1 HPV testing
This is a laboratory test in which cells from the cervix are tested for DNA from 
certain types of HPV that are known to cause cervical cancer. This may be done 
alone (primary HPV screening) or in combination with cervical cytology (hybrid 
HPV screening). These 2 screening strategies are meant to minimize unnecessary 
follow-up visits and invasive procedures without compromising the detection of 
disease.
5.1.1 Hybrid screening
This test is usually done using the sample of cells removed during a Pap smear test 
or Liquid Based Cytology (LBC). It is done if the results of a Pap smear test show cer-
tain abnormal cervical cells (reflex testing). When both the HPV test and Pap test are 
done using cells from the sample removed during a Pap test, it is called a Pap Smear/
HPV co-testing. Large-scale studies to evaluate management options for women 
with abnormal Pap smear results have been conducted and these studies indicate the 
potential utility of HPV DNA testing in the management of women with Pap smear 
results of Atypical Squamous Cells of Undetermined significance (ASCUS) [45–47]. 
Based on the results of these studies, screening strategy options that include testing 
for high-risk HPV DNA as an adjunct to cytology have been developed to triage and 
monitor ASCUS patients. These improvements in cytologic screening through LBC 
as well as the introduction of HPV DNA testing greatly facilitate the identification 
of women at risk for cervical cancer. There are three recommended options in the 
management of women with ASCUS [47] and these include:
5.1.1.1 Repeat cervical cytology
In this approach, ASCUS patients would undergo cytology at 4 to 6-month inter-
vals until two negative results are obtained after which the patient can be returned 
to routine cytologic screening. If any repeat cytology shows ASCUS or greater, 
referral to colposcopy is recommended.
5.1.1.2 Immediate colposcopy
If this is used, women with biopsy-confirmed CIN are treated as per standard 
protocol for management of cervical intraepithelial neoplasia (CIN) using exci-
sion or coagulation techniques. If biopsy is negative for CIN, patients will undergo 
repeat cytology at 12 months. In postmenopausal women who have ASCUS and 
clinical or cytologic evidence of atrophy, a 6-week course of intravaginal estrogen is 
recommended if there are no contraindications to estrogen use. A repeat cytology is 
performed after completion of the estrogen regimen and if this is negative, the test 
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is repeated in 4 to 6 months. If the repeat test shows ASCUS or greater, the patient is 
referred to colposcopy. Immunosuppressed women with ASCUS should be referred 
directly to colposcopy.
5.1.1.3 HPV DNA testing
This the most preferred approach especially if liquid-based cytology (LBC) is 
used or if specimens are co-collected for HPV DNA testing. If HPV DNA testing 
is negative for high-risk HPV types, the patient undergoes repeat cytology testing 
at 12 months. However, direct referral to colposcopy is recommended for women 
who test positive for any of the high-risk HPV types. If biopsy confirms CIN, 
patients are treated per standard protocol for management of CIN. If biopsy does 
not confirm CIN, then cytology should be repeated at 6 and 12 months with referral 
back to colposcopy if results show ASCUS or greater or repeat HPV DNA testing at 
12 months with referral back to colposcopy if high-risk HPV types are detected.
5.1.2 Primary HPV screening
HPV DNA testing alone without a Pap smear test may also be used for screening 
in women aged 25 years and older [48, 49]. It is as effective as a hybrid screening 
strategy that uses cytology in women aged 25–29 years and co-testing in those at 
30 years or older [49]. However, HPV primary screening requires less screening 
frequency (every 5 years). This involves direct referral to colposcopy for women 
who test positive for HPV types 16/18 and cytology for those who test positive for 
any of the other high-risk HPV types [50]. The International Agency for Research 
on Cancer (IARC) and the World Health Organization (WHO) have endorsed HPV 
testing as the primary screening method for cervical cancer. Several developed 
countries are now changing to HPV primary screening [50–52].
5.2 HPV vaccination
One of the major prevention strategies for cervical cancer is vaccination against 
HPV infection among adolescents prior to their first sexual exposure [15]. HPV 
vaccines are composed of virus-like particles (VLPs), which contains the major and 
minor HPV capsid antigens but lacking viral DNA. The vaccines are produced by 
expressing the L1 or L1 and L2 ORFs in eukaryotic cells. These proteins then self-
assemble into VLPs which are highly immunogenic. There is no cross-protection 
among the HPV types due to the high level of antigenic specificity of HPV capsid 
antigens and thus protection against each HPV type requires vaccination with 
VLPs of that type. Optimal vaccines would contain a cocktail of VLPs of the most 
common high-risk HPV subtypes. There are currently 2 commonly used vaccines 
(Bivalent and Quadrivalent) which protect against both HPV 16 and 18, which are 
known to cause at least 70% of cervical cancers. In addition, the quadrivalent vac-
cine also protects against HPV types 6 and 11 which cause anogenital warts. Both 
vaccines are more effective if administered prior to exposure to HPV and thus, it is 
preferable to administer them before first sexual activity. The WHO recommends 
vaccination for girls aged 9–13 years as this is the most cost-effective public health 
measure against cervical cancer [1, 53, 54]. Some countries have started to vaccinate 
boys as the vaccination prevents genital cancers in males as well as females, and 
the quadrivalent vaccine also prevents genital warts in males and females. These 
vaccines may provide some cross-protection against other less common HPV types 
which cause invasive cervical cancer. At present, vaccination against HPV is not rec-
ommended as a replacement for cervical cancer screening and in countries where 
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the vaccine is introduced, cervical screenings still need to be developed or further 
strengthened [53]. However, in most developing countries, there is still a generally 
low level of awareness of the existence and availability of these HPV vaccines [55] 
compared to the developed countries with well-organized cervical cancer screening 
and HPV vaccination programs. Recently, a nonavalent vaccine against HPV types 
6, 11, 16, 18, 31, 33, 45, 52 and 58, which has shown a better impact compared to the 
bivalent and quadrivalent vaccine, has been approved by the US Food and Drug 
Administration (FDA) and is now commercially available [56].
Other recommended preventive interventions against HPV infections that are 
appropriate for both boys and girls are education about safe sexual practices includ-
ing delayed onset of sexual activity; promotion and provision of condoms for those 
already engaged in sexual activity; male circumcision; and warnings about tobacco 
smoking.
5.3 Future perspectives
5.3.1 Measurement of HPV oncoprotein levels
Measuring the levels of HPV E6/E7 oncoproteins is now a potential biomarker 
for high-risk HPV infection and this may have a role in the future screening of 
women for high-risk HPV especially type 16 which accounts for more than 50% of 
all cervical cancer cases [57–59]. The E6/E7 oncoproteins are overexpressed after 
HPV invasion into the host cervical cells in the form of HPV DNA or viral integra-
tion into the host’s genome and are closely related to the development of cervical 
cancers [60]. In a recent pilot study, HPV16 E6/E7 oncoprotein test has a satisfac-
tory diagnostic value for cervical cancer screening and demonstrated a better 
sensitivity than cytological test and a better specificity than HPV DNA testing [61].
5.3.2 Therapeutic HPV vaccines
There are currently no approved therapeutic vaccines against HPV in humans. 
However, there are many recent studies that have generated promising vaccine 
candidates tested in clinical trials [62–64]. Despite the success of these vaccine 
candidates, there still remains the concern that conventional expression methods 
when fully developed might result in very expensive products [65, 66] that will be 
inaccessible to the resource-constraint countries who have the highest incidences of 
cervical cancer.
6. Executive summary/conclusions
Molecular and epidemiologic studies have solidified the association between 
high-risk strains of genital HPV and squamous cell carcinoma of the cervix. The 
incidence of cervical cancer and its associated mortality have declined in recent 
years, largely due to the widespread implementation of screening programs. 
Screening for cervical cancer remains an important public health and economic 
concern throughout the world. Large-scale studies to evaluate management options 
for women with abnormal Pap smear results have been conducted and these studies 
highlighted the potential utilization of HPV DNA testing in the management of 
women with ASCUS Pap smear results. From these studies, screening strategies that 
include testing for high-risk HPV DNA as an adjunct to cytology have been devel-
oped for the triage and surveillance of women with ASCUS. Several other studies, 
such as the ATHENA study [45], have also examined and confirmed the role of HPV 
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DNA testing as a primary screening for cervical precursor lesions. In addition to the 
changes in screening strategies, HPV 16 testing through measurement of HPV E6/
E7 oncoprotein levels and effective therapeutic HPV vaccines that have the potential 
to contribute significantly to the control and prevention of cervical cancer are also 
currently being developed for future use.
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